The invention provides methods of detection and monitoring of polyomavirus reactivation and active polyomavirus infections using a biological fluid sample. Also provided are methods of risk assessment and risk monitoring of developing a polyomavirus-associated disease.

Methods, compositions, devices, and kits are described herein that are useful for detecting BoHV-1 infection in animals and/or for distinguishing animals that may benefit from administration of BoHV-1 tmv vaccine.

A fusion protein is provided which is based on a self-assembling gene-regulatory NSP10 protein and a protein or peptide capable of being fused to NSP10 without interfering with the assembly or aggregation of the resulting fusion protein. The disclosure also relates to any nanoparticle formed thereby whether complete or not, and methods for the use of the NSP10 fusion protein are also disclosed, including use as vaccines for any indication in humans or animals, therapeutic methods involving the use of the fusion proteins such as using the protein to targeted an antibody or receptor, such as for treating or diagnosing cancer, biosensors using the fusion protein, or the use of the fusion proteins in cell sorting or any imaging application.

The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimerc structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.

The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.

The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

This technology relates in part to optical methods for analyzing particles, including nanoparticles, thereby determining their presence, identity, origin, size and/or number in a sample of interest.

Provided is a method for evaluating the severity of the dengue virus infection in an individual, executed by means of detecting a biological sample of an individual in vitro. The method comprises: detecting whether a non-structural protein 1 is present in a biological sample in vitro to obtain a first detection result; detecting whether a complex is present in the biological sample in vitro to obtain a second detection result, wherein the complex comprises the non-structural protein 1 and a thrombin, or comprises the non-structural protein 1 and a prothrombin; and evaluating the severity of the dengue virus infection in the individual via the first detection result and the second detection result. Also provided are a detection device and a detection kit for evaluating the severity of the dengue virus infection in an individual.

The present invention relates to composition derivable from a bifidobacteria, methods and uses thereof, for use in modulating the immune system in a subject by affecting viral action and/or viral effects in said subject. Furthermore, said composition may also be used in reducing the risk of development and exacerbation of chronic respiratory diseases such as asthma and COPD in a subject; preferably by modulating the immune system in the subject by affecting viral action and/or viral effects in said subject.

A modified nanoparticle includes a nanoparticle, a dispersibility improving group bound to a surface of the nanoparticle, and an oligosaccharide that is bound to the surface of the nanoparticle, and that selectively captures a specific virus or bacterium. A reagent for detection of a specific virus or bacterium by resistive pulse sensing is also provided, the reagent including the modified nanoparticle.